PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Bimekizumab - Psoriasis

PAD Profile : Bimekizumab - Psoriasis

Keywords :
Biologic, NICE, immunosuppressant, interleukin (IL) 17RA inhibitor, DMARD, bDmard, Disease modulating, Dermatology,
Brand Names Include :
Bimzelx

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
Psoriasis - High cost immunomodulator treatment pathway - October 23.pdf
31 October 2026
Evidence Review
Bimekizumab for moderate to severe plaque psoriasis- NICE briefing - October 2021.pdf
Webpage
NICE TA723 - Bimekizumab for moderate to severe plaque psoriasis - September 2021

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.

06 October 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve bimekizumab as a treatment option for the treatment of severe plaque psoriasis in line with NICE TA723. The current Psoriasis high cost immunomodulator treatment pathway is available below.
Increased frequency of dosing is agreed for those patients with a body weight ≥ 120 kg who did not achieve complete skin clearance during induction.

Bimekizumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians).

Increased frequency of dosing is agreed for those patients with a body weight ≥ 120 kg who did not achieve complete skin clearance during induction.
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.”

Associated BNF Codes

13. Skin
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More